Abraham, J. E., O’Connor, L. O., Grybowicz, L., Alba, K. P., Dayimu, A., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., Worley, J. R., Chhabra, M. A., Qian, W., Brown, J., Hardy, R., Vallier, A., Chan, S., Cidon, M. E. U., Sherwin, E., Chakrabarti, A., Sadler, C., Barnes, J., Persic, M., Smith, S., Raj, S., Borley, A., Braybrooke, J. P., Staples, E., Scott, L. C., Palmer, C. A., Moody, M., Churn, M. J., Pilger, D., Zagnoli-Vieira, G., Wijnhoven, P. W. G., Mukesh, M. B., Roylance, R. R., Schouten, P. C., Levitt, N. C., McAdam, K., Armstrong, A. C., Copson, E. R., McMurtry, E., Galbraith, S., Tischkowitz, M., Provenzano, E., O’Connor, M. J., Earl, H. M. (2025). Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial. Nature Communications. https://doi.org/10.1038/s41467-025-59151-0